Medical therapy of epilepsy: when to initiate treatment and when to combine?
Most patients reporting more than one well-documented or witnessed seizure require prophylactic antiepileptic (AED) therapy. Those with an underlying brain disorder and/or an abnormal electroencephalogram should probably be treated after their first event. The goal should be maintenance of a normal lifestyle by complete seizure control with no or minimal side-effects. Failure of the first AED due to lack of efficacy implies refractoriness. A policy of consecutive substitutions is unlikely to be an effective strategy. Thus, if the first or second monotherapy improves control but does not produce seizure freedom, an AED with different and perhaps multiple mechanisms of action should be added. Strategies for combining drugs should involve individual assessment of patient-related factors, including seizure type and epilepsy syndrome classifications coupled with an understanding of the pharmacology, side-effects and interaction profile of the AEDs. Reducing the dose of one or more AEDs may help accommodate the introduction of a second or third drug. An orderly approach to the pharmacological management and, when appropriate, surgical investigations for each epilepsy syndrome will optimise the chance of perfect seizure control and help more people achieve safer and more fulfilled lives.
Brodie
Martin J
MJ
Epilepsy Unit, Western Infirmary, Glasgow, G11 6NT, Scotland, UK. Martin.J.Brodie@clinmed.gla.ac.uk
D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D004554:Electric Countershock; D004827:Epilepsy / Q000628:therapy*; D006801:Humans; D011612:Psychosurgery; D013997:Time Factors; D017211:Treatment Failure; D016896:Treatment Outcome
D000927:Anticonvulsants
Neurology. 2001 Dec 26;57(12):2259-64
11756607
Epilepsia. 2001 Oct;42(10):1255-60
11737159
Lancet. 2001 Jan 20;357(9251):216-22
11213111
Neurology. 2003 Jan 28;60(2):162-3
12552025
Lancet. 2000 Jul 22;356(9226):323-9
11071202
Epilepsia. 1997 May;38(5):570-5
9184603
Neurology. 1991 Jul;41(7):965-72
2067659
Epilepsy Res. 1997 Mar;26(3):423-32
9127723
Lancet. 1998 Mar 28;351(9107):958-9
9734949
Epilepsia. 2000 Nov;41(11):1364-74
11077449
BMJ. 1990 Nov 17;301(6761):1112-4
2252920
Neurology. 2003 Aug 26;61(4):432-3
12939411
Epilepsy Res. 2002 Jun;50(1-2):67-70
12151118
CNS Drugs. 2001 Jan;15(1):1-12; discussion 13-5
11465010
Neurology. 2002 Apr 23;58(8 Suppl 5):S2-8
11971127
Epilepsia. 1999 Aug;40(8):1141-6
10448829
N Engl J Med. 2000 Feb 3;342(5):314-9
10660394
Seizure. 2002 Sep;11(6):349-51
12160660
Epilepsy Res. 1995 Oct;22(2):65-95
8777903
Neurology. 2003 Jan 28;60(2):186-90
12552028
Neurology. 1997 Oct;49(4):991-8
9339678
Arch Neurol. 1983 Dec;40(13):797-802
6416232
Lancet. 2002 May 25;359(9320):1790-1
12044369
Trends Pharmacol Sci. 2001 Sep;22(9):445-6
11592262
Pharmacol Ther. 2001 Apr;90(1):21-34
11448723
N Engl J Med. 2001 Aug 2;345(5):311-8
11484687
Seizure. 2003 Oct;12(7):413-43
12967570
Epilepsia. 2004 Sep;45(9):1141-9
15329080
N Engl J Med. 1999 May 20;340(20):1565-70
10332020
Epilepsy Res. 2003 Nov;57(1):1-13
14706729
Seizure. 2002 Mar;11(2):77-84
11945093
Seizure. 2000 Oct;9(7):464-8
11034869
Neurology. 2003 Feb 25;60(4):538-47
12601090
N Engl J Med. 1998 Jun 11;338(24):1715-22
9624191